-+ 0.00%
-+ 0.00%
-+ 0.00%

NRx Pharmaceuticals Receives FDA Letter Regarding Comments On Minor Formatting Changes To Proposed Label For Its Preservative-Free Ketamine Product, The Company Expects To Submit Final Label In April

Benzinga·04/06/2026 11:05:06
Listen to the news
  • NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory review.
  • NRx previously received a preliminary determination of bioequivalence for this product.
  • The Company continues to anticipate a decision on approval under the Generic Drug User Fee Act (GDUFA) in Summer 2026.